A Phase 2 interventional study of TR-701 200 mg and TR-701 300 mg in Skin Diseases, Infectious and Skin Diseases, Bacterial, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 12 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-11-25.
Sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Skin Diseases, Bacterial with a site in United States — 1 open to participants now, 2 under way, 1 of them phase 3. Skin Diseases, Bacterial · United States.
Among the 22 studies in Skin Diseases, Bacterial with a site in United States, this one is the 15th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2008, is one of 9 in phase 2, and was the 8th registered.
37 studies on the registry are indexed under Skin Diseases, Bacterial; 2 are open to participants now.
Browse Skin Diseases, Bacterial studies →1 of the 22 studies in Skin Diseases, Bacterial with a site in United States is open now. Recruiting first, the newest first:
MoonLake Immunotherapeutics AG · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1 Skin Diseases, Bacterial study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2008.
This study's enrollment of 192 is below the median of 249 across 29 interventional studies indexed under Skin Diseases, Bacterial.
Median enrollment 234 across the 21 interventional studies. Of the 20 that completed or were terminated, 15 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), one of the names counted as Merck & Co., Inc. Under that name alone:
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 19 studies on the registry; none are open to participants now.
Merck & Co., Inc has 3 studies filed under Skin Diseases, Bacterial — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Skin Diseases, Bacterial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine the oral dosage of TR-701 to be used in Phase III studies in patients with complicated skin and skin structure infections.
37 studies on the registry are indexed under Skin Diseases, Bacterial; 2 are open to participants now.
This study's enrollment of 192 is below the median of 249 across 29 interventional studies indexed under Skin Diseases, Bacterial.
Browse Skin Diseases, Bacterial studies →Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 19 studies on the registry; none are open to participants now.
First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc.
Compared within Skin Diseases, Bacterial, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Skin Diseases, Infectious. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: TR-701 200 mg
Drug: TR-701 300 mg
Drug: TR-701 400 mg
oral TR-701 200 mg for 5 to 7 days
oral TR-701 300 mg for 5 to 7 days
TR-701 400 mg for 5 to 7 days
Clinical Response Rate at Test of Cure in the Clinically Evaluable Analysis Set
Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.
Time frame: 7 to 14 days after the last dose of study drug
Clinical Response Rate at Test of Cure in the Clinical Modified Intent to Treat Analysis Set
Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.
Time frame: 7-14 days after last dose of study drug
Response Rate at End of Therapy
Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.
Time frame: last day of study treatment
Microbiological Response Rate at Test of Cure in the Microbiologically Evaluable Analysis Set
Satisfactory microbiological outcomes are eradication and presumed eradication
Time frame: 7-14 days after last dose of study drug
Clinical Outcome at the Late Follow-up Visit in the Clinical Modified Intent to Treat Analysis Set
Persistent clinical cure was defined as continuing favorable response.
Time frame: 21 to 28 days after the last study drug
To Evaluate the Safety Profile of Tedizolid Phosphate
Time frame: Multiple
Population PK
Time frame: Multiple
Microbiological Recurrence at Late Follow-up in Clinical Modified Intent to Treat Analysis Set
Time frame: 21-28 days after last study drug
| Milestone | TR-701 200 mg | TR-701 300 mg | TR-701 400 mg |
|---|---|---|---|
| Started | 64 | 64 | 64 |
| Completed | 55 | 60 | 56 |
| Not completed | 9 | 4 | 8 |
| Withdrew: Randomized but didn't receive drug | 1 | 1 | 2 |
| Withdrew: Lost to follow-up | 6 | 3 | 6 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Bacteremia | 1 | 0 | 0 |
Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.
| Percentage of participants | TR-701 200 mg | TR-701 300 mg | TR-701 400 mg |
|---|---|---|---|
| Clinical Response Rate at Test of Cure in the Clinically Evaluable Analysis Set | 98.2 (90.4 to 100) | 94.4 (84.6 to 98.8) | 94.4 (84.6 to 98.8) |
Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.
| Percentage of participants | TR-701 200 mg | TR-701 300 mg | TR-701 400 mg |
|---|---|---|---|
| Clinical Response Rate at Test of Cure in the Clinical Modified Intent to Treat Analysis Set | 88.9 (78.4 to 95.4) | 88.9 (78.4 to 95.4) | 85.5 (74.2 to 93.1) |
Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.
| Percentage of participants | TR-701 200 mg | TR-701 300 mg | TR-701 400 mg |
|---|---|---|---|
| Response Rate at End of Therapy | 93.7 (84.5 to 98.2) | 90.5 (80.4 to 96.4) | 91.9 (82.2 to 97.3) |
Satisfactory microbiological outcomes are eradication and presumed eradication
| Percentage of participants | TR-701 200 mg | TR-701 300 mg | TR-701 400 mg |
|---|---|---|---|
| Microbiological Response Rate at Test of Cure in the Microbiologically Evaluable Analysis Set | 100 (91.8 to 100) | 93.2 (81.3 to 98.6) | 100 (92.3 to 100.0) |
Persistent clinical cure was defined as continuing favorable response.
| Percentage of Participants | TR-701 200 mg | TR-701 300 mg | TR-701 400 mg |
|---|---|---|---|
| Clinical Outcome at the Late Follow-up Visit in the Clinical Modified Intent to Treat Analysis Set | 96.4 | 98.2 | 98.1 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
| Percentage of participants | TR-701 200 mg | TR-701 300 mg | TR-701 400 mg |
|---|---|---|---|
| Microbiological Recurrence at Late Follow-up in Clinical Modified Intent to Treat Analysis Set | 0 (0 to 6.4) | 0 (0 to 6.4) | 0 (0 to 6.7) |
Collected over Adverse events were to be collected after informed consent through last visit (up to 36 days).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TR-701 200 mg | — | 2/63 (3.2%) | 40/63 (63.5%) |
| TR-701 300 mg | — | 1/63 (1.6%) | 44/63 (69.8%) |
| TR-701 400 mg | — | 2/62 (3.2%) | 43/62 (69.4%) |
| Event | TR-701 200 mg | TR-701 300 mg | TR-701 400 mg |
|---|---|---|---|
| Suicidal ideationPsychiatric disorders | 0/63 | 0/63 | 1/62 |
| AbcessInfections and infestations | 1/63 | 0/63 | 1/62 |
| Cholecystitis acuteHepatobiliary disorders | 0/63 | 1/63 | 0/62 |
| CellulitisInfections and infestations | 1/63 | 0/63 | 0/62 |
| Event | TR-701 200 mg | TR-701 300 mg | TR-701 400 mg |
|---|---|---|---|
| NauseaGastrointestinal disorders | 10/63 | 12/63 | 13/62 |
| HeadacheNervous system disorders | 5/63 | 10/63 | 6/62 |
| AbscessInfections and infestations | 5/63 | 8/63 | 7/62 |
| DiarrheaGastrointestinal disorders | 7/63 | 3/63 | 6/62 |
| VomitingGastrointestinal disorders | 7/63 | 6/63 | 6/62 |
| Skin infectionInfections and infestations | 4/63 | 2/63 | 2/62 |
| Blood pressure increasedInvestigations | 1/63 | 4/63 | 2/62 |
| DizzinessNervous system disorders | 4/63 | 1/63 | 0/62 |
| InsomniaPsychiatric disorders | 1/63 | 4/63 | 1/62 |
| Skin lesionSkin and subcutaneous tissue disorders | 4/63 | 2/63 | 1/62 |
All randomized participants who received study drug.
| Age, Continuous(years) | TR-701 200 mg | TR-701 300 mg | TR-701 400 mg | Total |
|---|---|---|---|---|
| Mean | 37.3 ± 12.1 | 36.0 ± 12.4 | 35.8 ± 12.0 | 36.4 ± 12.1 |
| Sex: Female, Male(Participants) | TR-701 200 mg | TR-701 300 mg | TR-701 400 mg | Total |
|---|---|---|---|---|
| Female | 20 | 24 | 22 | 66 |
| Male | 43 | 39 | 40 | 122 |
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Sep 2008 to primary completion in Feb 2009, 5 months.
Results were first posted in Aug 2014, 5 years 5 months after primary completion. A results delay was requested in Apr 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tedizolid phosphate
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) →